Month: July 2020

Telia Lietuva, AB (toliau – „Telia Lietuva“ arba Bendrovė) valdyba patvirtino auditorių netikrintas Telia Lietuva, AB konsoliduotas tarpines finansines ataskaitas, parengtas pagal ES priimtus Tarptautinius finansinės atskaitomybės standartus, ir konsoliduotą tarpinį pranešimą už šešių mėnesių laikotarpį, pasibaigusį 2020 m. birželio 30 dieną.2020 m. antrasis ketvirtis:– Bendrosios pajamos sudarė 97,1 mln. eurų ir, palyginti su 2019 m. antrojo ketvirčio pajamomis – 92 mln. eurų, padidėjo 5,6 procento.– EBITDA, neįskaičius vienkartinių sąnaudų, palyginti su 2019 m. antrojo ketvirčio EBITDA, neįskaičius vienkartinių sąnaudų, – 31,2 mln. eurų, buvo 6,6 proc. didesnė ir siekė 33,3 mln. eurų.– Laikotarpio pelnas buvo 11,4 mln. eurų ir, palyginti su 12,9 mln. eurų pelnu prieš metus, sumažėjo 11,5 proc. dėl didesnių pelno mokesčio...

Today, Schibsted released its Q2 2020 results.Highlights of the quarterEBITDA of NOK 498 million for Schibsted excluding Adevinta; -11% YoY while significantly higher than Q1 2020.Acquisition of Finnish online marketplace Oikotie from Sanoma announced on 16 July 2020Nordic Marketplaces: Revenues declined 11 percent YoY (currency adjusted) due to COVID-19 while trends have improved throughout the quarter. Cost savings led to EBITDA margin of 52 percent in Norway and 42 percent in Sweden.News Media: Continuous good trend for digital subscriptions, advertising revenue decline has improved throughout the quarter. Cost savings led to an EBITDA margin of 8 percent. Cost program implementation on track.Financial Services: Underlying revenue decline in Lendo due to COVID-19 while marketing spend has been reduced to curb EBITDA decline. Stable...

Highlights first half 2020Strong H1 2020 sales growth of 9.9% to € 103.5 million. Sales in Benelux amounted to € 92.3 million (+10.5% like for like) and New Business amounted to € 11.2 million (+5.4% like for like).In Q2 sales growth of 12.0% to € 49.1 million. Benelux amounted to € 44.5 million (+14.2% like for like) and New Business amounted to € 4.6 million (+7.8% like for like) respectively.High order intake levels have resulted in record level order book of € 23.5 million (+60.2% versus 30 June 2019), creating a solid buffer given the unprecedented times upcoming.Order intake in Benelux in Q2 (+56.6% like for like) and New Business (+23.2% like for like) resulting in H1 increase in order intake of +22.5% like for like.Online sales for the Group has grown 71.4%, leading to a channel share of 14.0% particularly due to a strong performance...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPANBasel, Switzerland, July 17, 2020Following the closing of the tender offer period on July 16, 2020, at 4 p.m. (CEST), Basilea Pharmaceutica Ltd. (“Basilea” or the “Company”) today announces the first results of its partial repurchase offer (“Repurchase Offer”) for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022 (ISIN: CH0305398148; SSN: 30’539’814, the “Bonds”) as follows (“First Results Announcement”):The Company previously announced that it placed and provisionally allocated CHF 125 million senior unsecured convertible bonds due 2027 (the “New Bonds”).The results of...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPANBasel, Schweiz, 17. Juli 2020Nach dem Ende der Angebotsfrist am 16. Juli 2020, 16.00 Uhr (MESZ), gibt Basilea Pharmaceutica AG („Basilea“ oder die „Gesellschaft“) heute die ersten Ergebnisse ihres Teilrückkaufangebots („Rückkaufangebot“) für mindestens CHF 90 Millionen und höchstens CHF 110 Millionen Nennwert ihrer ausstehenden Wandelanleihen mit Fälligkeit 2022 (ISIN: CH0305398148; SSN: 30’539’814, die „Anleihen“ und jeder Anleihenstitel die „Obligation“) wie folgt bekannt („Erste Ergebnispublikation“):Die Gesellschaft gab zuvor bekannt, dass sie vorrangige ungesicherte Wandelanleihen in Höhe von CHF 125 Millionen mit Fälligkeit 2027 (die „Neuen Anleihen“) platziert und vorläufig zugeteilt hat.Das Ergebnis...

CALGARY, Alberta, July 17, 2020 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce the concurrent extension of its second lien term loan (“Term Loan”) and Revolving Credit Facility (“RCF”) and the completion of the RCF lenders’ 2020 annual review.  The Company’s board of directors has also approved its third quarter 2020 capital budget. SECOND LIEN TERM LOAN EXTENSIONPetrus has entered into an amending agreement with Macquarie Bank Limited to extend the $35 million Term Loan maturity date to July 31, 2021.  The interest rate on the Term Loan balance will be updated to become the Canadian Dealer Offered Rate (“CDOR”) plus 975 basis points.  All of the interest will be made by way of payment-in-kind (“PIK”) and added to the outstanding balance...

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the pricing of its global offering of an aggregate of 11,000,000 new ordinary shares (the “Global Offering”).HighlightsAnticipated gross proceeds of approximately US$74.3 million (or US$85.4 million if the underwriters exercise their option to purchase additional ADSs in full), before deducting underwriting discounts and commissions and estimated offering expenses payable by RenalytixAIRenalytixAI intends to use approximately US$25.0 to US$30.0 million of the net proceeds from the Global Offering for the continued development...

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of its common stock at a price to the public of $24.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $175.0 million. The offering is expected to close on July 21, 2020, subject to customary closing conditions.  Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,093,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.  All of the shares...

HIGHLIGHTS

MIAMI, July 16, 2020 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) announced today that it has priced its underwritten public offering of 16,666,667 ordinary shares of the Company (the “Offering”) at a price to the public of $15.00 per share. The Company has granted the underwriters an option to purchase up to 2,500,000 of additional ordinary shares, which option must be exercised on or before August 17, 2020.The Offering is expected to close on July 21, 2020, subject to customary closing conditions. The Company expects to use the net proceeds from the Offering for general corporate purposes.J.P. Morgan, Citigroup, Goldman Sachs & Co. LLC, Barclays, Mizuho Securities and UBS Investment Bank are acting as joint book-running managers for the Offering.The Offering is being made under an automatic...